Note:
In pair#1 (i.e. HNSCC-1 and its HTX) the candidate drivers were AKT2 and CASP8.
In pair #2 (i.e. HNSCC-2 and its HTX) the key drivers appear to be BCL9 and ROS1.
In pair#3 (i.e HNSCC-1 and its HTS) JAK3 and SYK are putative candidate drivers.
Enriched pathway derived point mutations in primary and HTX pair identified genes largely involved in MAPK, TGFpathways at least in case of pair #2 and #3.
Additionally, ABLIM1 (in pair #2) and ROCK 2 (in pair #3) -both linked to axon guidance, pathways in cancer and colorectal cancer associated genes like BAX, FGFR2 and TCF7L2 were covered by both these pairs.
In contrast, pair #1 demonstrated predominantly shared mutation in genes linked to mTOR and oncogenic KRAS activation. In addition to previously identified genetic alterations (TP53, PTEN, NOTCH1) the novel mutations (AKT2, ROCK, ROS, JAK3, SYK) were found in primary tumors. 
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Supplementary Methods
Patient enrolment and treatment
Patients diagnosed with locally advanced Head and Neck Squamous
Cell viability assay
Tumor cell viability was assessed by Cell Counting Kit-8 (CCK-8) (Dojindo. CK04-13).
Briefly, one tenth volume of CCK-8 solution was added to each well containing tissue slices and incubated at 37 °C for 4 h in a CO 2 incubator under humidified condition. The absorbance was measured at 450 nm using a microplate reader (Bio-Rad). Cell viability was assessed with appropriate controls.
In vitro ATP utilization assay
Thirty micro molar ATP was spiked to the explant culture and further incubated for 30 min at a standard culture condition. ATP level was determined using StayBrite ATP assay system (BioVision, K791-100). The ATP utilization was calculated by subtracting the ATP levels in the explant free control (blank) from treated and untreated explants groups.
Histopathological analysis
A part of tumor tissue was fixed in 10% buffered formalin and embedded in paraffin (FFPE).
Five micron FFPE tissue sections were stained with hematoxylin and eosin (H&E). All tumors were graded according to standard pathological criteria. The tumor content and tumor-stroma ratio of tissues was also assessed for developing histology score similar to method described previously 1 .
Immunohistochemical (IHC) analysis
Formalin fixed paraffin embedded (FFPE) tissue sections were serially collected to maintain basic histological features. The tissue sections were de-paraffinized followed by rehydration.
The sections were incubated with Antigen Unmasking Solution (Vector Laboratories. H-3300) for 10 min followed by retrieval using a microwave for 30 min. Endogenous hydrogen peroxidase was quenched by incubating the sections with 3% H 2 O 2 (Merck.
61868505001730) for 15 min and washed in running tap water for 3 min followed by a wash in 1x PBS for 7 min. Protein blocking was performed using 10% goat serum (Vector Laboratories. 5-1000) for 1 h at room temperature. Tissue sections were incubated with following primary antibodies: anti human Ki-67 (rabbit polyclonal from Vector Laboratories, was done by exposure of tissues to DAB substrate (DAB Peroxidase Substrate Kit; Vector Laboratories, SK-4100). Color development was monitored under light microscope.
Appropriate negative antibody control (Isotype matched IgG) and/or tissue/cell line positive/negative controls were used accordingly. The tissues were counterstained using Papanicolaous solution (Merck. 60925301251730) and sections were mounted using DPX mountant medium. Each IHC result was evaluated by two independent experts and whenever there were differences in observation both experts came to a consensus Changes in the frequency of proliferating or dividing population of tumor cells in the explant tissues were evaluated using Ki-67 scoring (mean of total number of positive cells per field per section in triplicates) 2 . Phospho IHC score for EGFR and Met was analyzed based on combined value of percent positive area (0-100 scale) and intensity (0-3 scale) 3 .
TUNEL assay
Apoptotic cells were detected by TUNEL method (ApopTag Peroxidase In Situ Apoptosis Detection Kit; Millipore. S7100). The effects of drugs in explants were determined based on viability of tissues at T0 time points (base line) and 72 h along with DMSO treated control.
Briefly, the serial tissue sections were deparaffinized and rehydrated in graded ethanol. °C in a humidified chamber. The reaction was terminated by washing the sections in stop/wash buffer for 10 min. Anti-digoxigenin conjugate was added to tissues and incubated for 30 min at RT. Chromogenic development was done by exposure of tissues to DAB substrate. The sections were counterstained using 0.5% methyl green.
Gene expression and microarray analysis
RNA later stabilized tissue samples were lysed using sample lysis buffer and total RNA was isolated. Total RNA was subsequently assessed for integrity by bio-analyzer and quantified by nanodrop for microarray experiments. RNA with 7 or above RIN value was used for microarray experiments. Approximately 50 ng of total RNA extracted from tumor samples was reverse transcribed to generate cy3 labeled amplified cRNA and was profiled using Agilent Kit and Agilent Sure Print G3 Human GE 8x60K Platform (Agilent Technologies.
G4851B. http://www.chem.agilent.com). The array data obtained were normalized using feature extraction software and analyzed using GeneSpring Software. Data were expressed as fold differences (both for up-regulated and down-regulated genes) compared to the corresponding control. Any difference that was below 1.5 fold was considered as insignificant for further validation. A heat map was generated and relationship (similarity of genes) was elucidated among different primary and xenograft tumor samples. Similarly, AS and TMP treated explant tissues were also subjected to gene expression profiling. 
Mutational analysis
Genomic DNA was extracted from tumor tissues using QIAamp DNA Micro Kit (Qiagen.
56304) and subjected to PCR using region-specific primers to detect the mutational status of KRAS (codon numbers 12, 13, 61 and 146) by sequencing. Briefly, DNA fragment containing KRAS mutation hotspots were amplified with intron-based primers in reaction medium containing 2.5 mM MgCl2, 0.2 mM dNTPs, 1 μM of each primer, and 0.5 U of Phusion Taq (Life Technologies. F-530S) in a total volume of 50 μl. The PCR was carried out at 95 °C for 5 min, followed by 25 cycles at 95 °C for 30 sec; 60 °C for 30 sec; 72 °C for 30 sec with a final extension for 5 min. The PCR products were resolved on 1.5% agarose gels. The amplicons were excised and purified using QIAquick gel extraction kit (Qiagen. 28704) according to manufacturer's protocol and processed for Sanger sequencing.
Quantitative PCR
RNA later stabilized tissues were lysed using micro-dismembrator (Sartorius) and total RNA was isolated from pulverized tissues using an RNeasy Micro kit (Qiagen. 74004). The quality 
Exome sequence analysis
Genomic DNAs were isolated from primary HNSCC tumors using DNAeasy Tissue Kit according to manufacturer's protocol (Qiagen. 56304). The quality of DNA was performed by spectrophotometry and DNA with A260/A280 ratio between 1.7 and 1.9 was used for further processing. Additionally, the DNA integrity was also checked by EcoRI digestion followed by gel analysis. Following quality check, exome sequencing of the DNAs was conducted at BGI Americas (Philadelphia, PA). The qualified genomic sample was randomly fragmented with a base pair peak of 150-200 bp followed by adaptor ligation on both ends of the fragment. The adaptor ligated templates were purified by Agencourt AMPure SPRI beads. Fragments with insert size ~200 bp were excised. Extracted DNA was amplified by ligation mediated PCR, purified and hybridized to the SureSelect Biotinylated RNA library for enrichment. Hybridized fragments were bound to the streptavidin beads whereas non-hybridized fragments were washed out after 24 h. Captured LM-PCR products were subjected to Agilent 2100
Bioanalyzer to estimate the magnitude of enrichment. Each captured library was then loaded on Hiseq2000 platform, and high-throughput sequencing was performed for each captured library independently to ensure that each sample meets the desired average fold-coverage. . Significantly mutated genes/gene sets linked to specific pathways were determined for both primary and HTXs and aligned in a pair wise fashion.
The tumor driver pathway analysis was performed to dissect the candidate drivers for these tumors.
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